Pharma Equity Group | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

37,307 results for “Pharma Equity Group”

Trials

View all 22853 →

Active, not recruiting

Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care

416 participants · First posted Apr 9, 2021

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

200 participants · First posted Feb 16, 2024

Contraceptive Equity Study 2016

1,015 participants · First posted Jan 6, 2017

Drugs

View all 1654 →

Irinotecan hydrochloride liposomal (Luye Pharma Group)

BTK inhibitors (Shenogen Pharma Group)

Streptococcus A Group（Luya Pharma）

Organizations

View all 1730 →

ASCENTAGE PHARMA GROUP INTL

China

Ascentage Pharma Group Inc.

United States

Luye Pharma Group Ltd.

China

News

View all 11070 →

Pharma Equity Group Receives Regulatory Approval for Phase II Trial of RNX-011 in Secondary Peritonitis

Reponex Pharmaceuticals Secures European Patent for Inflammatory Bowel Disease Treatment Targeting $4.7 Billion Market

Reponex Pharmaceuticals Prioritizes Clinical Programs for Colon Cancer, Peritonitis, and IBD

Page 1 of 3731